Patrizia Dell'Orto
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023; 34:397-409.
25.01.2023Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
25.01.2023Ann Oncol 2023; 34:397-409
Luen Stephen J, Viale Giuseppe, Nik-Zainal S, Savas Peter, Kammler Roswitha, Dell'Orto Patrizia, Biasi Olivia Maria, Degasperi A, Brown Louise C, Láng István, MacGrogan Gaëtan, Tondini Carlo, Bellet Meritxell, Villa F, Bernardo A, Ciruelos Eva, Karlsson Per, Neven Patrick, Climent Miguel A, Müller-Hübenthal Boris, Jochum Wolfram, Bonnefoi Hervé R, Martino Silvana, Davidson Nancy E, Geyer Charles E, Chia S K, Ingle James N, Coleman Robert E, Solbach Christine, Thürlimann Beat, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Fleming Gini F, Francis Prudence A, Speed T P, Regan Meredith M, Loi Sherene
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat 2019; 176:557-568.
07.05.2019Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
07.05.2019Breast Cancer Res Treat 2019; 176:557-568
Denkert Carsten, Müller Volkmar, Klauschen Frederick, Ataseven Beyhan, Engels Knut, Kammler Roswitha, Pfitzner Berit M, Dietel Manfred, Fasching Peter A, Colleoni Marco, Blohmer Jens-Uwe, Mehta Keyur, Budczies Jan, Regan Meredith M, Loibl Sibylle, Dell'Orto Patrizia, von Minckwitz Gunter, Mastropasqua Mauro G, Solbach Christine, Thürlimann Beat, Viale Giuseppe
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Luen S, Regan M, Colleoni M, Viale G, Thürlimann B, Hackl W, Dolan S, JeBailey L, Demanse D, Biasi O, Dell'Orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial. JAMA Oncol 2018
14.06.2018Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
14.06.2018JAMA Oncol 2018
Luen Stephen J, Regan Meredith M, Colleoni Marco, Viale Giuseppe, Thürlimann Beat, Hackl Wolfgang, Dolan Sinead, JeBailey Lellean, Demanse David, Biasi Olivia Maria, Dell'Orto Patrizia, Kammler Roswitha, Savas Peter, Lee Chee Khoon, Asher Rebecca, Loi Sherene
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Bartlett J, Rea D, Dowsett M, Cuzick J, Viale G, Forbes J, Brookes C, Van de Velde C, Putter H, Seynaeve C, Thürlimann B, Dell'Orto P, Mallon E, Sestak I, Regan M, Ahmed I. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer 2017; 79:129-138.
08.05.2017HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
08.05.2017Eur J Cancer 2017; 79:129-138
Bartlett John M S, Rea Daniel W, Dowsett Mitchell, Cuzick Jack, Viale Giuseppe, Forbes John F, Brookes Cassandra L, Van de Velde Cornelis J H, Putter Hein, Seynaeve Caroline, Thürlimann Beat, Dell'Orto Patrizia, Mallon Elizabeth A, Sestak Ivana, Regan Meredith M, Ahmed Ikhlaaq
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Leyland-Jones B, Maibach R, Price K, Coates A, Goldhirsch A, Gelber R, Pagani O, Viale G, Rae J, Regan M, Arnould L, Neven P, Harvey V, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, BIG 1-98 Collaborative Group. ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat 2015; 154:543-55.
21.11.2015ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
21.11.2015Breast Cancer Res Treat 2015; 154:543-55
Leyland-Jones Brian, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Pagani Olivia, Viale Giuseppe, Rae James M, Regan Meredith M, Arnould Laurent, Neven Patrick, Harvey Vernon, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, BIG 1-98 Collaborative Group
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Regan M, Sessa F, Peg Cámara V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 2015
22.10.2015Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
22.10.2015Breast Cancer Res Treat 2015
Regan Meredith M, Sessa Fausto, Peg Cámara Vicente, Rodríguez Peralto José Luis, MacGrogan Gaëtan, Colleoni Marco, Goldhirsch Aron, Price Karen N, Coates Alan S, Gelber Richard D, Viale Giuseppe, Öhlschlegel Christian, Pizzolitto Stefano, Pagani Olivia, Francis Prudence A, Fleming Gini F, Walley Barbara A, Kammler Roswitha, Dell'Orto Patrizia, Russo Leila, Szőke János, Doimi Franco, Villani Laura, SOFT and TEXT Investigators and International Breast Cancer Study Group
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Leyland-Jones B, Neven P, Treilleux I, Rasmussen B, Maibach R, Price K, Coates A, Goldhirsch A, Pagani O, Viale G, Rae J, Harvey V, Ditzel H, Gray K, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Lyng M, Regan M. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 2015; 151:373-84.
03.05.2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
03.05.2015Breast Cancer Res Treat 2015; 151:373-84
Leyland-Jones Brian, Neven Patrick, Treilleux Isabelle, Rasmussen Birgitte Bruun, Maibach Rudolf, Price Karen N, Coates Alan S, Goldhirsch Aron, Pagani Olivia, Viale Giuseppe, Rae James M, Harvey Vernon J, Ditzel Henrik J, Gray Kathryn P, Abramovitz Mark, Bouzyk Mark, Young Brandon, Long Bradley, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Lyng Maria B, Regan Meredith M
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
06.03.2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
06.03.2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
03.11.2008Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
03.11.2008J Clin Oncol 2008; 26:5569-75
Viale Giuseppe, Olszewski Wojciech P, Knox Fiona, Thürlimann Beat, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Gusterson Barry A, Goldhirsch Aron, Orosz Zsolt, Neven Patrick, Öhlschlegel Christian, Giobbie-Hurder Anita, Regan Meredith M, Coates Alan S, Mastropasqua Mauro G, Dell'Orto Patrizia, Maiorano Eugenio, MacGrogan Gaëtan, Braye Stephen G, Breast International Group Trial 1-98
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
01.01.2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
01.01.2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
06.08.2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
06.08.2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S